Home > Resources > Company Profiles > SeraCare Life Sciences, Incorporated

SeraCare Life Sciences, Incorporated (SRLS)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Michael F. Crowley Jr. , CEO/President/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Michael F. Crowley Jr., CEO/President/Director

37 Birch Street

Milford, MA 01757

US Map it

Phone: (508) 244-6400

Fax: (508) 634-3394

www.seracare.com



Overview

Manufacturer and marketer of human and animal based diagnostic, therapeutic, and research products. Primary focus is the development and sale of human and animal blood-based diagnostic, therapeutic and research products to customers.

News From Around the Web
News
powered by inform

Employees

Number of Employees: 204
Revenue per Employee: $217,322

Top Executives

Thomas Lawlor, COO
Jerry L. Burdick, CFO/Director/Secretary

Board of Directors

Robert J. Cresci, Director
Jerry L. Burdick, CFO/Director/Secretary
Tim T. Hart, CPA, CFO

Samuel Anderson, Director
Barry D. Plost, Chairman of the Board/Director

Financials

Quarterly
Annual

Income Statement 09/2008 08/2005 05/2005 02/2005
Sales 10.59 Mil. 7.54 Mil. 7.64 Mil. 6.71 Mil.
Gross Operating Profit -5.24 Mil. 6.63 Mil. 7.15 Mil. 6.29 Mil.
Operating Income before D & A (EBITDA) -11.71 Mil. 3.54 Mil. 4.22 Mil. 3.69 Mil.
Total Income Before Interest Expenses (EBIT) -22.66 Mil. 3.61 Mil. 3.79 Mil. 3.29 Mil.
Total Net Income -18.75 Mil. 1.93 Mil. 1.98 Mil. 1.68 Mil.
Basic EPS, Total -1.37 0.17 0.2 0.17
Diluted EPS, Total -1.32 0.16 0.18 0.15

BALANCE STATEMENT 09/2008 08/2005 05/2005 02/2005
Cash and Equivalents 9.52 Mil. 29.67 Mil. 1.26 Mil. 337 K.
Total Assets 25.49 Mil. 75.86 Mil. 45.6 Mil. 41.36 Mil.
Total Liabilities 5.41 Mil. 16.04 Mil. 16.79 Mil. 16.02 Mil.
Total Capitalization 52.64 Mil. 107.72 Mil. 75.78 Mil. 73.47 Mil.

Cash Flow 09/2008 08/2005 05/2005 02/2005
Net Cash From Continuing Operations -10.65 Mil. -1.71 Mil. -825 K. -944 K.
Net Cash From Investing Activities 1.52 Mil. -459.88 K. 526 K. 19 K.
Net Cash From Financing Activities 5.09 Mil. 30.37 Mil. 83 K. -214 K.
Net Change in Cash & Cash Equivalents -4.04 Mil. 28.2 Mil. -216 K. -1.14 Mil.

powered by Interactive Data

Income Statement 2008 2004 2003 2002
Sales 32.48 Mil. 17.31 Mil. 15.93 Mil. 17.84 Mil.
Gross Operating Profit 14.82 Mil. 11.13 Mil. 7.27 Mil. 7.47 Mil.
Operating Income before D & A (EBITDA) -269.94 K. 6.03 Mil. 3.04 Mil. 3.58 Mil.
Total Income Before Interest Expenses (EBIT) -11.97 Mil. 5.42 Mil. 2.9 Mil. 3.65 Mil.
Total Net Income -13.16 Mil. 4.16 Mil. 2.62 Mil. 3.62 Mil.
Basic EPS, Total -0.83 0.51 0.35 0.49
Diluted EPS, Total -0.83 0.45 0.31 0.44

BALANCE STATEMENT 2008 2004 2003 2002
Cash and Equivalents 9.52 Mil. 1.48 Mil. 2.99 Mil. 4.82 Mil.
Total Assets 25.49 Mil. 40.93 Mil. 19.74 Mil. 15.62 Mil.
Total Liabilities 5.41 Mil. 17.01 Mil. 7.43 Mil. 2.71 Mil.
Total Capitalization 52.64 Mil. 71.73 Mil. 20.42 Mil. 17.28 Mil.

Cash Flow 2008 2004 2003 2002
Net Cash From Continuing Operations -10.65 Mil. -429.33 K. -453.77 K. 3 Mil.
Net Cash From Investing Activities 1.52 Mil. -31.64 Mil. -4.01 Mil. -383.56 K.
Net Cash From Financing Activities 5.09 Mil. 30.56 Mil. 2.63 Mil. 0
Net Change in Cash & Cash Equivalents -4.04 Mil. -1.51 Mil. -1.83 Mil. 2.61 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Hi-Tech Pharmacal Co., Inc.
121.8 Mil.
RXElite, Incorporated
41.46 Mil.
Catalyst Pharmaceutical Partners, Incorporated
39.96 Mil.
Lotus Pharmaceuticals, Incorporated
37.41 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented